8-K: IO Biotech's Cylembio Misses Primary Endpoint in Melanoma Trial

IO Biotech announced Phase 3 trial results for Cylembio in advanced melanoma, showing clinical improvement in progression-free survival but narrowly missing statistical significance on the primary endpoint.

Summary

• Topline results from the pivotal Phase 3 IOB-013 trial of Cylembio in combination with pembrolizumab for first-line advanced melanoma were announced.
• The study enrolled 407 patients, with 203 receiving Cylembio plus pembrolizumab and 204 receiving pembrolizumab alone.
• The primary endpoint, progression-free survival (PFS), showed a median PFS of 19.4 months for the combination arm versus 11.0 months for pembrolizumab alone, with a hazard ratio of 0.77 (95% CI: 0.58-1.00).
• The p-value of 0.056 narrowly missed the study's statistical significance threshold of p<=0.045.
• A trend toward improved overall survival (OS) was observed (HR 0.79), with OS data expected to mature in the next six to nine months.
• A profound effect was seen in PD-L1 negative tumors, with mPFS of 16.6 months for the combination versus 3.0 months for monotherapy (HR: 0.54, nominal p=0.006).
• In patients without prior anti-PD-1 treatment, mPFS was 24.8 months for the combination versus 11.0 months for monotherapy (HR: 0.74, nominal p=0.037).
• The combination was well tolerated with no new safety signals; injection site reactions were the most common adverse event (56% in combination arm).
• The company estimates a cash and cash equivalents balance of approximately $28.1 million as of June 30, 2025, which, combined with a $12.5 million loan drawn on July 4, 2025, is sufficient into Q1 2026.

Sentiment

Score: 5

Explanation: While the primary endpoint was narrowly missed, the strong clinical improvement in PFS, particularly in difficult-to-treat subgroups like PD-L1 negative patients, and the favorable safety profile are significant positives. The company's plan to engage with the FDA for potential BLA submission indicates confidence despite the statistical miss. However, the miss on the primary endpoint introduces regulatory uncertainty and potential delays, balancing the positive clinical data.

Positives

• Cylembio plus pembrolizumab achieved a median progression-free survival (PFS) of 19.4 months, significantly longer than 11.0 months for pembrolizumab alone.
• PFS improvement was observed across virtually all subgroups, including those with poor prognostic factors.
• A profound effect was demonstrated in patients with PD-L1 negative tumors, with a median PFS of 16.6 months for the combination versus 3.0 months for pembrolizumab monotherapy (HR: 0.54, nominal p=0.006).
• In a post hoc analysis of patients without prior anti-PD-1 treatment, the combination achieved a median PFS of 24.8 months versus 11.0 months for monotherapy (HR: 0.74, nominal p=0.037).
• A trend toward improved overall survival (OS) was observed (HR 0.79), with OS data expected to mature over the next six to nine months.
• The combination was well tolerated, with no new safety signals observed and no significant added systemic toxicity compared to pembrolizumab monotherapy.
• The company has sufficient cash and cash equivalents, including a recent loan draw, to meet working capital requirements into the first quarter of 2026.
• Global supply chain and manufacturing are in place at commercial scale.

Negatives

• The primary endpoint of progression-free survival (PFS) narrowly missed statistical significance (p=0.056) against the study's threshold (p<=0.045).
• The cash and cash equivalents balance of $28.1 million as of June 30, 2025, is a preliminary estimate and may differ materially upon completion of financial closing procedures.

Risks

• The preliminary estimate of cash and cash equivalents as of June 30, 2025, may differ materially from final results upon completion of financial closing procedures.
• Forward-looking statements, including those regarding the timing or outcome of communications with the FDA, BLA submission, Cylembio launch, and future clinical trials, are subject to inherent risks and uncertainties, some of which cannot be predicted or quantified.
• Actual results and other events may differ materially from those expressed or implied in forward-looking statements due to numerous risks and uncertainties.

Future Outlook

IO Biotech plans to meet with the U.S. Food and Drug Administration (FDA) this fall to discuss the totality of the Phase 3 data for Cylembio and determine the next steps for submission of a Biologics License Application (BLA) for the treatment of advanced melanoma. The company also intends to present more detailed results from the IOB-013 study at an upcoming medical meeting. Overall survival data from the trial is expected to mature over the next six to nine months. The company is also advancing other Cylembio trials in solid tumors and has preclinical pipeline candidates.

Management Comments

• "In this study, we observed a highly encouraging improvement in progression free survival and consistent trend in overall survival in patients treated with Cylembio. The magnitude and durability of clinical effect observed consistently across subgroups supports our confidence in Cylembio and its potential as a treatment for advanced melanoma patients. We look forward to engaging with the FDA to determine a potential path to approval based on these data." Mai-Britt Zocca, PhD, President and CEO.
• "Patients treated with Cylembio in combination with pembrolizumab have achieved the longest median PFS ever observed in a Phase 3 clinical study in advanced melanoma, and in the PD-L1 negative population, patients achieved a remarkable 16.6 months of median PFS, compared to 3.0 months in patients treated with pembrolizumab alone. The significant benefit seen across patients with poor prognostic factors, including PD-L1 negative patients, cannot be overlooked. Given the notable safety profile and the strong clinical effect observed with Cylembio, as well as the unmet need in advanced melanoma patients, Cylembio, if approved, has the potential to become a new standard of care for patients with advanced melanoma." Omid Hamid, MD, Director, Clinical Research and Immunotherapy at The Angeles Clinic and Research Institute.
• "Delaying progression and improving survival is the ultimate treatment goal for patients and although overall survival is not yet mature, the trend we are seeing in OS with separation of the curves is encouraging, with a consistent PFS clinical improvement and OS trend favoring the combination arm across virtually all subgroups, with no new safety signals or significant additional systemic toxicity." Qasim Ahmad, MD, Chief Medical Officer.

Industry Context

The announcement relates to the advanced melanoma treatment landscape, an area with a high unmet medical need where approximately 50% of patients progress within one year of treatment. The global melanoma drug market is valued at $5.6 billion and is growing at 9%. Cylembio, if approved, could address this need by offering a new first-line treatment option, particularly for patients with poor prognostic factors like PD-L1 negative tumors, where current options are less effective.

Comparison to Industry Standards

• Cylembio + pembrolizumab achieved a median PFS of 19.4 months in this study.
• Pembrolizumab monotherapy (control arm in this study) achieved 11.0 months PFS.
• Comparatively, other treatments in advanced melanoma have shown: Opdualag (Nivo+Rela) with 10.2 months PFS (vs. Nivo 4.6m), Ipi/Nivo (CM-067) with 11.5 months PFS (vs. Ipi 6.9m), and Pembro KN-006 with 11.6 months PFS (vs. Ipi 4.1m).
• The 19.4 months median PFS observed with Cylembio in combination with pembrolizumab is stated to be the "longest median PFS ever observed in a Phase 3 clinical study in advanced melanoma."
• The profound effect in PD-L1 negative patients (16.6 months mPFS vs. 3.0 months for pembrolizumab alone) highlights a significant improvement in a difficult-to-treat subgroup.

Stakeholder Impact

• Shareholders: Potential for significant value creation if Cylembio gains regulatory approval, but immediate uncertainty due to the primary endpoint miss. The cash runway provides stability into Q1 2026.
• Patients: Potential for a new, highly effective, and well-tolerated first-line treatment option for advanced melanoma, especially for those with PD-L1 negative tumors who currently have limited options.
• Healthcare Providers: Cylembio could become a new standard of care, offering an improved PFS benefit and favorable safety profile compared to existing treatments.
• Employees: Continued development and potential commercialization of Cylembio could lead to growth and stability.
• Creditors (EIB): The company has drawn on its loan facility, indicating continued operations and progress towards milestones.

Next Steps

• Meet with regulatory authorities (FDA) this fall to discuss the totality of data and determine next steps for submission of a Biologics License Application (BLA) for advanced melanoma.
• Present more detailed results from the IOB-013 study at an upcoming medical meeting.
• Overall survival (OS) data from the IOB-013 study is expected to mature over the next six to nine months.
• Initial data from the IOB-032 Phase 2 neo-adjuvant/adjuvant solid tumors trial expected in 2H25.
• Continue readiness for IND submission for IO112 (Arginase 1 target).
• Potential US approval and launch of Cylembio in 2026.
• Potential EU MAA submission in 2026.

Key Dates

Recommendation

While the Phase 3 trial for Cylembio narrowly missed its primary statistical significance endpoint, the clinical data presented shows a substantial improvement in median progression-free survival (19.4 months vs. 11.0 months) and a profound effect in the difficult-to-treat PD-L1 negative subgroup. The observed trend in overall survival and the favorable safety profile are also encouraging. The company's intent to pursue regulatory discussions with the FDA suggests a potential path to approval despite the statistical miss. However, the regulatory uncertainty introduced by missing the primary endpoint warrants caution. Investors should hold to monitor FDA feedback, the maturation of overall survival data, and the company's strategic path forward, as these will be critical determinants of future value.

Keywords

IO Biotech, IOBT, Cylembio, Pembrolizumab, KEYTRUDA, Melanoma, Advanced Melanoma, Cancer Vaccine, Phase 3 Trial, PFS, Progression-Free Survival, Oncology, Biotechnology, Clinical Trial Results, FDA Submission, Biologics License Application, Immunotherapy, PD-L1 negative, T-win platform